Last reviewed · How we verify

The treatment of investigator choice — Competitive Intelligence Brief

The treatment of investigator choice (The treatment of investigator choice) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

phase 3 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

The treatment of investigator choice (The treatment of investigator choice) — LintonPharm Co.,Ltd.. The treatment of investigator choice works by targeting the underlying cause of the disease.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
The treatment of investigator choice TARGET The treatment of investigator choice LintonPharm Co.,Ltd. phase 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). The treatment of investigator choice — Competitive Intelligence Brief. https://druglandscape.com/ci/the-treatment-of-investigator-choice. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: